Profile data is unavailable for this security.
About the company
Immutep Limited is an Australia-based late-stage biotechnology company. The Company is focused on developing novel immunotherapies for cancer and autoimmune disease. It is focused on advancement of therapeutics related to Lymphocyte Activation Gene-3 (LAG-3), and its diversified product portfolio harnesses LAG-3’s ability to stimulate or suppress the immune response. Its lead clinical candidate is eftilagimod alfa (efti or IMP321) for the treatment of different types of cancers. Efti is the Company’s first-in-class novel immunotherapy that directly activates the immune system to fight cancer, which is under evaluation in TACTI-004 (KEYNOTE-F91), a registrational Phase III trial for the first-line therapy of advanced or metastatic non-small cell lung cancer. Its second in-house product candidate (IMP761) which is in clinical development for the treatment of autoimmune disease, a third product candidate, IMP731, a depleting antibody that could remove T cells involved in autoimmunity.
- Revenue in AUD (TTM)60.10k
- Net income in AUD-61.43m
- Incorporated1987
- Employees19.00
- LocationImmutep LtdPlaza Building, L 12 95 Pitt StSYDNEY 2000AustraliaAUS
- Phone+61 28315-7003
- Fax+61 28569-1880
- Websitehttps://www.immutep.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Island Pharmaceuticals Ltd | 58.80k | -3.92m | 113.00m | -- | -- | 13.86 | -- | 1,921.80 | -0.0224 | -0.0224 | 0.0003 | 0.0303 | 0.0117 | -- | 0.1099 | -- | -77.95 | -72.12 | -90.37 | -81.53 | -- | -- | -6,666.91 | -19,239.15 | -- | -162.89 | 0.00 | -- | 1,148.41 | -- | -36.86 | -- | -- | -- |
| Arovella Therapeutics Ltd | 525.53k | -7.51m | 118.92m | 14.00 | -- | 5.86 | -- | 226.28 | -0.0067 | -0.0067 | 0.0005 | 0.0169 | 0.0301 | -- | -- | -- | -43.05 | -75.94 | -47.90 | -90.89 | -- | -- | -1,428.87 | -2,386.13 | -- | -- | 0.00 | -- | 237.44 | -1.82 | 14.14 | -- | 1.23 | -- |
| Paradigm Biopharmaceuticals Ltd | 7.11m | -18.77m | 136.61m | -- | -- | 5.79 | -- | 19.23 | -0.047 | -0.047 | 0.0183 | 0.0544 | 0.2684 | -- | 1.14 | -- | -70.91 | -67.55 | -80.99 | -75.98 | 99.71 | 99.24 | -264.18 | -527.01 | -- | -9,722.29 | 0.0003 | -- | 10.29 | 8.87 | 68.04 | -- | -- | -- |
| Actinogen Medical Ltd | 685.26k | -14.73m | 140.45m | -- | -- | 7.62 | -- | 204.95 | -0.005 | -0.005 | 0.0002 | 0.0058 | 0.0299 | -- | 0.0907 | -- | -64.34 | -53.87 | -76.58 | -59.25 | -- | -- | -2,149.88 | -3,680.96 | -- | -231.81 | 0.1511 | -- | 135.46 | 48.76 | -12.94 | -- | 10.81 | -- |
| Nyrada Inc | 2.56m | -4.85m | 199.63m | -- | -- | 48.06 | -- | 78.02 | -0.0243 | -0.0243 | 0.0128 | 0.017 | 0.4566 | -- | -- | -- | -86.47 | -48.87 | -112.02 | -53.88 | -- | -- | -189.37 | -195.83 | -- | -- | 0.00 | -- | -24.81 | 18.93 | -248.28 | -- | -- | -- |
| Dimerix Ltd | 5.91m | -13.25m | 300.20m | 0.00 | -- | 22.37 | -- | 50.76 | -0.0239 | -0.0239 | 0.0106 | 0.0224 | 0.096 | -- | 22.53 | -- | -21.50 | -48.20 | -27.12 | -68.49 | -- | -- | -224.08 | -932.89 | -- | -- | 0.0072 | -- | 913.54 | 365.69 | 22.39 | -- | -- | -- |
| Cogstate Ltd | 75.68m | 14.46m | 372.27m | 61.00 | 26.10 | 5.37 | 19.95 | 4.92 | 0.0831 | 0.0831 | 0.4349 | 0.4042 | 0.866 | -- | 4.69 | -- | 16.55 | 11.82 | 20.98 | 16.38 | 60.53 | 56.32 | 19.11 | 14.87 | -- | -- | 0.0097 | -- | 22.25 | 18.44 | 86.15 | -- | -0.4007 | -- |
| Racura Oncology Ltd | 788.42k | -4.79m | 415.67m | -- | -- | 24.85 | -- | 527.22 | -0.0282 | -0.0282 | 0.0043 | 0.0922 | 0.0418 | -- | 11.64 | -- | -25.38 | -41.75 | -27.84 | -44.07 | -- | -- | -607.20 | -2,015.76 | -- | -- | 0.00 | -- | -5.30 | 142.92 | 65.36 | -- | -- | -- |
| Immutep Ltd | 60.10k | -61.43m | 545.28m | 19.00 | -- | 3.76 | -- | 9,072.83 | -0.0422 | -0.0422 | 0.00004 | 0.0984 | 0.0003 | -- | 0.0991 | -- | -34.27 | -32.47 | -36.64 | -34.65 | -- | -- | -102,219.90 | -21,963.05 | -- | -- | 0.0112 | -- | -49.76 | -62.18 | -43.82 | -- | 69.56 | -- |
| Opthea Ltd | 35.64k | -232.06m | 820.79m | 5.00 | -- | -- | -- | 23,031.23 | -0.19 | -0.19 | 0.00003 | -0.2328 | 0.0002 | -- | 0.1324 | -- | -132.57 | -123.14 | -- | -214.28 | -- | -- | -651,164.00 | -159,023.40 | -- | -11.15 | -- | -- | -79.95 | -15.80 | 26.09 | -- | 38.73 | -- |
| PYC Therapeutics Ltd | 26.17m | -50.30m | 871.97m | 23.00 | -- | 5.29 | -- | 33.32 | -0.0987 | -0.0987 | 0.0511 | 0.2824 | 0.1907 | -- | 66.76 | -- | -37.17 | -42.88 | -40.47 | -47.98 | -- | -- | -194.92 | -172.76 | -- | -39.28 | 0.006 | -- | 14.51 | 58.66 | -33.34 | -- | 55.85 | -- |
| Clarity Pharmaceuticals Ltd | 0.00 | -64.30m | 1.08bn | -- | -- | 10.33 | -- | -- | -0.2011 | -0.2011 | 0.00 | 0.2807 | 0.00 | -- | -- | -- | -50.27 | -40.38 | -54.18 | -43.70 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -51.91 | -- | 65.99 | -- |
| Holder | Shares | % Held |
|---|---|---|
| Regal Funds Management Pty Ltd.as of 07 Oct 2025 | 203.20m | 13.79% |
| MLC Investments Ltd.as of 07 Oct 2025 | 73.08m | 4.96% |
| Perennial Value Management Ltd.as of 07 Oct 2025 | 71.74m | 4.87% |
| IOOF Investment Services Ltd.as of 07 Oct 2025 | 55.35m | 3.76% |
| FIL Investment Management (Hong Kong) Ltd.as of 31 Dec 2025 | 33.05m | 2.24% |
| Vanguard Investments Australia Ltd.as of 31 Dec 2025 | 25.55m | 1.73% |
| Antares Capital Partners Ltd.as of 07 Oct 2025 | 14.64m | 0.99% |
| Norges Bank Investment Managementas of 30 Jun 2025 | 12.44m | 0.84% |
| FIL Pensions Managementas of 30 Jun 2025 | 11.87m | 0.81% |
| Netwealth Investments Ltd.as of 15 Aug 2025 | 11.13m | 0.76% |
